Roche Acquires Spark Therapeutics For $114.50 Per Share, A 122% Premium
February 25, 2019 at 07:23 AM EST
Spark Therapeutics announced that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction.
